It has also been suggested that SPP1 may be an effective therapeutic or diagnostic target in certain cancers, such as melanoma, breast, colorectal, head and neck, and lung cancer, as it appeared to correlate with poor clinical outcomes and promote tumor progression by interacting with carcinogenic genes and facilitating immune cell infiltration [179,180]. The gene discussed is SPP1; the disease is melanoma.